Overa Therapeutics is developing novel cancer therapies based on targeted cancer-gamete antigens. Their first target, SAS1B, was discovered at the University. The company is currently focused on a two-year research phase aimed at delivering a development candidate antibody-drug conjugate for testing in human trials.